QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NASDAQ:KMPH

KemPharm - KMPH Stock Forecast, Price & News

$5.39
-0.12 (-2.18%)
(As of 01/30/2023 04:31 PM ET)
Add
Compare
Today's Range
$5.36
$5.51
50-Day Range
$4.12
$6.27
52-Week Range
$4.00
$7.38
Volume
78,924 shs
Average Volume
246,833 shs
Market Capitalization
$185.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.25

KemPharm MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
221.2% Upside
$17.25 Price Target
Short Interest
Healthy
4.38% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of KemPharm in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$55,369 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.65) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

657th out of 1,049 stocks

Pharmaceutical Preparations Industry

334th out of 514 stocks


KMPH stock logo

About KemPharm (NASDAQ:KMPH) Stock

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KemPharm and its competitors with MarketBeat's FREE daily newsletter.

KMPH Stock News Headlines

KemPharm, Inc. (NASDAQ:KMPH) Short Interest Update
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
KemPharm Third Quarter 2022 Earnings: Misses Expectations
KemPharm to Report Third Quarter 2022 Financial Results
See More Headlines
Receive KMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KemPharm and its competitors with MarketBeat's FREE daily newsletter.

KMPH Company Calendar

Last Earnings
11/09/2022
Today
1/30/2023
Next Earnings (Estimated)
3/29/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KMPH
Employees
22
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.25
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+220.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-8,560,000.00
Net Margins
-328.56%
Pretax Margin
-335.26%

Debt

Sales & Book Value

Annual Sales
$10.72 million
Cash Flow
$0.24 per share
Book Value
$3.63 per share

Miscellaneous

Free Float
34,125,000
Market Cap
$185.98 million
Optionable
Optionable
Beta
2.26

Key Executives

  • Richard W. PascoeRichard W. Pascoe
    Chief Executive Officer & Director
  • Travis C. MickleTravis C. Mickle
    President & Director
  • R. LaDuane CliftonR. LaDuane Clifton
    Chief Financial Officer, Secretary & Treasurer
  • Sven Guenther
    Chief Scientific Officer
  • Timothy J. Sangiovanni
    Vice President & Controller













KMPH Stock - Frequently Asked Questions

Should I buy or sell KemPharm stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KemPharm in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KMPH shares.
View KMPH analyst ratings
or view top-rated stocks.

What is KemPharm's stock price forecast for 2023?

4 analysts have issued 12-month target prices for KemPharm's stock. Their KMPH share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $17.25 in the next twelve months. This suggests a possible upside of 218.3% from the stock's current price.
View analysts price targets for KMPH
or view top-rated stocks among Wall Street analysts.

How have KMPH shares performed in 2023?

KemPharm's stock was trading at $4.59 on January 1st, 2023. Since then, KMPH stock has increased by 18.1% and is now trading at $5.42.
View the best growth stocks for 2023 here
.

Are investors shorting KemPharm?

KemPharm saw a drop in short interest in January. As of January 15th, there was short interest totaling 1,370,000 shares, a drop of 16.0% from the December 31st total of 1,630,000 shares. Based on an average daily volume of 237,400 shares, the short-interest ratio is currently 5.8 days. Approximately 4.4% of the company's stock are sold short.
View KemPharm's Short Interest
.

When is KemPharm's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our KMPH earnings forecast
.

How were KemPharm's earnings last quarter?

KemPharm, Inc. (NASDAQ:KMPH) posted its earnings results on Wednesday, November, 9th. The specialty pharmaceutical company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The specialty pharmaceutical company earned $2.87 million during the quarter, compared to analyst estimates of $2.97 million. KemPharm had a negative trailing twelve-month return on equity of 16.12% and a negative net margin of 328.56%.

What other stocks do shareholders of KemPharm own?
When did KemPharm IPO?

(KMPH) raised $60 million in an IPO on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers.

What is KemPharm's stock symbol?

KemPharm trades on the NASDAQ under the ticker symbol "KMPH."

How do I buy shares of KemPharm?

Shares of KMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is KemPharm's stock price today?

One share of KMPH stock can currently be purchased for approximately $5.42.

How much money does KemPharm make?

KemPharm (NASDAQ:KMPH) has a market capitalization of $187.02 million and generates $10.72 million in revenue each year.

How can I contact KemPharm?

KemPharm's mailing address is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. The official website for the company is www.kempharm.com. The specialty pharmaceutical company can be reached via phone at (321) 939-3416, via email at jrando@tiberend.com, or via fax at 319-665-2577.

This page (NASDAQ:KMPH) was last updated on 1/30/2023 by MarketBeat.com Staff